Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study suggests that low-dose oral minoxidil is safe and effective in treating COVID-19 associated telogen effluvium, as indicated by a significant decrease in hair-shedding scores over follow-up visits.

This review discusses the increased incidence of hair loss and telogen effluvium among COVID-19 patients and evaluates existing evidence for regenerative treatments like PRP and HFSCs, finding limited published data.

This review summarizes findings on hair loss caused by COVID-19, noting that Telogen Effluvium frequently occurs in female patients 63 days post-infection, often in those with mild to moderate cases and certain comorbidities.

This systematic review found an increased incidence of hair loss and telogen effluvium among COVID-19 patients and reported preliminary effectiveness of platelet-rich plasma, adipose-derived mesenchymal stem cells, and human follicle stem cells for treatment without major side effects.

This article presents cases of two patients experiencing excessive hair shedding 2 to 3 months after COVID-19 infection, highlighting a possible link to telogen effluvium.